Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease

Author:
  • ELEditors From The Medical Letter
    Editors From The Medical Letter

Abstract
Lecanemab-irmb (Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer’s disease, has now received full approval from the FDA based on a trial showing that it slowed cognitive and functional decline in patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease dementia and confirmed presence of brain amyloid.